Suppr超能文献

合成齐墩果酸衍生物对高致病性冠状病毒的强抑制活性及作用模式:COVID-19候选药物

Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate.

作者信息

Soltane Raya, Chrouda Amani, Mostafa Ahmed, Al-Karmalawy Ahmed A, Chouaïb Karim, Dhahri Abdelwaheb, Pashameah Rami Adel, Alasiri Ahlam, Kutkat Omnia, Shehata Mahmoud, Jannet Hichem Ben, Gharbi Jawhar, Ali Mohamed A

机构信息

Department of Basic Sciences, Adham University College, Umm Al-Qura University, Adham 21971, Saudi Arabia.

Faculty of Sciences, Tunis El Manar University, Tunis 1068, Tunisia.

出版信息

Pathogens. 2021 May 19;10(5):623. doi: 10.3390/pathogens10050623.

Abstract

In late December 2019, a novel coronavirus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), escaped the animal-human interface and emerged as an ongoing global pandemic with severe flu-like illness, commonly known as coronavirus disease 2019 (COVID-19). In this study, a molecular docking study was carried out for seventeen () structural analogues prepared from natural maslinic and oleanolic acids, screened against SARS-CoV-2 main protease. Furthermore, we experimentally validated the virtual data by measuring the half-maximal cytotoxic and inhibitory concentrations of each compound. Interestingly, the chlorinated isoxazole linked maslinic acid (compound ) showed promising antiviral activity at micromolar non-toxic concentrations. Thoughtfully, we showed that compound mainly impairs the viral replication of SARS-CoV-2. Furthermore, a very promising SAR study for the examined compounds was concluded, which could be used by medicinal chemists in the near future for the design and synthesis of potential anti-SARS-CoV-2 candidates. Our results could be very promising for performing further additional in vitro and in vivo studies on the tested compound () before further licensing for COVID-19 treatment.

摘要

2019年12月下旬,一种新型冠状病毒,即严重急性呼吸综合征冠状病毒2(SARS-CoV-2),突破了动物与人的界限,引发了一场持续的全球大流行,导致严重的流感样疾病,即通常所说的2019冠状病毒病(COVID-19)。在本研究中,对由天然齐墩果酸和熊果酸制备的17种结构类似物进行了分子对接研究,这些类似物针对SARS-CoV-2主要蛋白酶进行了筛选。此外,我们通过测量每种化合物的半数最大细胞毒性浓度和抑制浓度,对虚拟数据进行了实验验证。有趣的是,氯化异恶唑连接的齐墩果酸(化合物 )在微摩尔无毒浓度下显示出有前景的抗病毒活性。经过深入研究,我们发现化合物 主要损害SARS-CoV-2的病毒复制。此外,还得出了一项针对所研究化合物非常有前景的构效关系研究结果,药物化学家在不久的将来可利用该结果设计和合成潜在的抗SARS-CoV-2候选药物。在该测试化合物( )获得COVID-19治疗的进一步许可之前,我们的结果对于对其进行进一步的体外和体内研究可能非常有前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f8e/8159111/dfc4dcd83a15/pathogens-10-00623-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验